top of page
Insights and News Curated for Life Science Experts by Life Science Experts....
INSIGHTS HUB
Warren Buffett’s Hiring Rule: Why Integrity Comes First
Warren Buffett’s hiring philosophy has long been quoted in business circles, and for good reason. As he prepares to step down as CEO of...
Deepfakes: A Growing Threat to Hiring in the Life Sciences Industry
As Life Sciences recruiting becomes more selective and AI has continued advancement, incorporating these technologies into recruitment...
The FTC Ban on Non-Competes – From Life Science Recruiters’ Perspective
In a landmark decision, the Federal Trade Commission (FTC) has voted 3-2 to approve the issuance of a final rule that could reshape the...
Search
$150M Deal: Regeneron and Tessera Collaborate on Gene Therapy for 200,000 AATD Patients
Tarrytown, NY and Somerville, MA, December 1, 2025 (Globe Newswire) -- Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to develop TSRA-196, an in vivo Gene Writing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting lungs and liver in roughly 200,000 people in the U.S. and Europe. The therapy aims to correct the underlying mutation and restore functional protein through a one-time durable treatment. Tessera will lead ini
Novocure Appoints Frank Leonard as CEO After 15+ Years Driving Growth
Baar, Switzerland and Portsmouth, NH, December 3, 2025 (Business Wire) -- Novocure (NASDAQ: NVCR) named Frank Leonard as its new Chief Executive Officer, effective immediately, following the resignation of Ashley Cordova. Leonard, previously Novocure’s President, has spent over 15 years leading global business operations and helping launch the company’s device-based cancer therapies. William Doyle, Executive Chairman, highlighted Leonard’s pivotal role in shaping Novocure’s
Solventum to Acquire Acera Surgical for $725M Plus $125M in Milestones, Expanding into Synthetic Tissue Matrices
St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings. Read full article here .
Baird Medical Names Mark Saxton as CEO
New York, December 3, 2025 (PRNewswire) -- Baird Medical appointed Mark Saxton as CEO of its U.S. subsidiary, bringing over 25 years of medtech leadership including experience at NeuroPace, Smith + Nephew, and Covidien. Saxton will lead U.S. operations, driving the expansion of Baird’s minimally invasive Microwave Ablation (MWA) platform. Read full article here .
bottom of page